<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Adv Pharm Technol Res</journal-id><journal-id journal-id-type="iso-abbrev">J Adv Pharm Technol Res</journal-id><journal-id journal-id-type="publisher-id">JAPTR</journal-id><journal-title-group><journal-title>Journal of Advanced Pharmaceutical Technology &#x00026; Research</journal-title></journal-title-group><issn pub-type="ppub">2231-4040</issn><issn pub-type="epub">0976-2094</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28516058</article-id><article-id pub-id-type="pmc">5416657</article-id><article-id pub-id-type="publisher-id">JAPTR-8-63</article-id><article-id pub-id-type="doi">10.4103/japtr.JAPTR_162_16</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Comparison of amoxicillin and metronidazole effect on three-drug regimen for the treatment of <italic>Helicobacter pylori</italic> infection in children</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kasiri</surname><given-names>Karam-Ali</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Khoshdel</surname><given-names>Abolfazl</given-names></name><xref ref-type="aff" rid="aff2">1</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Karimi</surname><given-names>Afshin</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib><contrib contrib-type="author"><name><surname>Sedehi</surname><given-names>Morteza</given-names></name><xref ref-type="aff" rid="aff4">3</xref></contrib><contrib contrib-type="author"><name><surname>Kasiri</surname><given-names>Niloufar</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib></contrib-group><aff id="aff1">Department of Pediatrics, Shahrekord University of Medical Sciences, Shahrekord, Iran</aff><aff id="aff2"><label>1</label>Biochemistry Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran</aff><aff id="aff3"><label>2</label>Shahrekord University of Medical Sciences, Shahrekord, Iran</aff><aff id="aff4"><label>3</label>Department of Epidemiology and Biostatistics, Shahrekord University of Medical Sciences, Shahrekord, Iran</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Abolfazl Khoshdel, Biochemistry Research Center, Shahrekord University of Medical Sciences, Rahmatiyeh, Shahrekord, Iran. E-mail: <email xlink:href="nikakhosh@gmail.com">nikakhosh@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Apr-Jun</season><year>2017</year></pub-date><volume>8</volume><issue>2</issue><fpage>63</fpage><lpage>66</lpage><permissions><copyright-statement>Copyright: &#x000a9; 2017 Journal of Advanced Pharmaceutical Technology &#x00026; Research</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><p><italic>Helicobacter pylori</italic> is an important risk factor for chronic gastritis, peptic ulcer, and gastric cancer. Three-drug regimen is the first-line treatment for this infection, but the response rate to treatment varies in different geographical regions. This study was conducted to comparatively determine the effect of amoxicillin and metronidazole on three-drug regimen to treat <italic>H. pylori</italic> infection in 1&#x02013;15-year-old children. This clinical trial was conducted on 82 patients aged 1&#x02013;15 years with convenience sampling referring to the Endoscopy Unit of Hajar Hospital, Shahrekord. Group 1 was administered with clarithromycin, amoxicillin, and omeprazole (CAO), and Group 2 with, clarithromycin, metronidazole, and omeprazole (CMO). One month after completion of the treatment, stool antigen test was used to study the eradication of <italic>H. pylori</italic>. Data were analyzed using SPSS software by Chi-square test. Three of the 82 patients were excluded from the study because of side effects caused by drugs. Nearly 87.2% of the patients in CAO-treated group and 92.5% in CMO-treated group had response to treatment. There was no significant difference in eradication rate between the two regimens (<italic>P</italic> = 0.43). The two regimens displayed no superiority over each other for eradicating <italic>H. pylori</italic> infection and response rate to treatment in children aged 1&#x02013;15 years.</p></abstract><kwd-group><title>Key words</title><kwd>Amoxicillin</kwd><kwd>clarithromycin</kwd><kwd><italic>Helicobacter pylori</italic></kwd><kwd>metronidazole</kwd><kwd>omeprazole</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p><italic>Helicobacter pylori</italic> is a spiral, Gram-negative, microaerophilic bacterium with polar flagella, which was first isolated from the end lining tissue of human stomach in 1982[<xref rid="ref1" ref-type="bibr">1</xref>] <italic>H. pylori</italic> is a human stomach-specific pathogenic bacterium which has colonized in at least half of the whole population of the world.[<xref rid="ref2" ref-type="bibr">2</xref>]</p><p>Many studies have reported the decrease in the efficiency of this regimen because of increased resistance to clarithromycin and have recommended a new regimen to be introduced. However, this regimen remains to result in a good eradication in the regions with low prevalence of resistance to <italic>H. pylori</italic>.[<xref rid="ref3" ref-type="bibr">3</xref>] We decided to compare the eradication rate of two three-drug regimens, clarithromycin, amoxicillin, and omeprazole (CAO) and clarithromycin, metronidazole, and omeprazole (CMO) for <italic>H. pylori</italic> infection to investigate their efficacy for <italic>H. pylori</italic> eradication in Chaharmahal and Bakhtiari province, southwest Iran.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>MATERIALS AND METHODS</title><p>This randomized clinical trial was conducted on 82 symptomatic patients with the following inclusion criteria: patients having symptoms (dyspepsia, epigastric pain, gastrointestinal bleeding, etc.) for 1 month to 2 years, not responding to outpatient treatment, and being 1&#x02013;15 years old. The patients were admitted to the educational center of Hajar hospital, Shahrekord, Southwest Iran, for endoscopy. On performing endoscopy, we obtained two specimens from the patients' gastric tissue. A specimen was used for rapid urease test (RUT) and the other one was sent to the laboratory for pathology examination using hematoxylin and eosin that is the only method that can detect other <italic>H. pylori</italic>-associated lesions (atrophy, intestinal metaplasia, etc.).[<xref rid="ref4" ref-type="bibr">4</xref><xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref6" ref-type="bibr">6</xref>] In general, serologic assays cannot be used on their own in children and adolescents for either diagnosis of <italic>H. pylori</italic> infection or to monitor the success of therapy because the sensitivity and specificity for the detection of antibodies (IgG or IgA) against <italic>H. pylori</italic> in children vary widely.[<xref rid="ref7" ref-type="bibr">7</xref>] After 24 h, the results of RUT were prepared. All the patients with positive RUT result of gastric tissue biopsy specimens after 24 h or positive pathology results were included in the study. The exclusion criteria were patients with previous treatment for <italic>H. pylori</italic> infection, antibiotic therapy within 4 weeks prior to endoscopy, malignancy or suspected malignancy, gastrectomy, acquisition of severe hepatic disease or any severe diseases within the past 2 years, and having no compliance with the administered regimens. Patients fulfilling the therapy prerequisites were enrolled and informed about the research and related procedures. The patients were fully informed of the research purposes. Written consent was filled by all patients. Then, the patients enrolled were randomly assigned to two groups of 41 each, underwent treatment in one of the Groups of A or B. The patients in Group A were administered with CAO regimen and those in Group B were administered with CMO. The patients administered with CAO received 1&#x02013;2 mg/kg omeprazole twice a day for 1 month, and simultaneously 50 mg/kg amoxicillin and 15 mg/kg clarithromycin twice a day for 2 weeks.[<xref rid="ref8" ref-type="bibr">8</xref>] The patients administered with CMO should receive 1 mg/kg omeprazole twice a day divided into two doses for 1 month and simultaneously 20 mg/kg metronidazole and 15 mg/kg clarithromycin twice a day for 2 weeks.</p><p>After the patients completed filling out checklists of the demographic data, they were informed of their next referring which was the date of the completion of regimens taking. The patients were told that they should inform the research team if any problems occur to them, particularly side effects or any other problems leading to the discontinuation of regimens taking. If a patient was not able to follow regimen for any reasons such as side effects, withdrawal from the study, and no tolerance, he/she was excluded from the study.</p><p>The patients were revisited after completion of regimens and were told to undergo stool antigen test using monoclonal immunochromatography 1 month later for the detection of <italic>H. pylori</italic> eradication.[<xref rid="ref9" ref-type="bibr">9</xref>] The patients were informed of the exact date of stool antigen test and were reminded of not using proton pump inhibitor (PPI) and antibiotics till stool antigen test. The test results were recorded in the patients' checklists. The data of checklists were analyzed using SPSS version 22 (Armonk, NY: IBM Corp.) by chi-square test.</p></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><p>Overall, 82 patients were enrolled in this study, and three patients, two in CAO group and one in CMO group, were excluded from the study because of side effects. The two groups were matched by age and there was no significant difference in age between them [<xref ref-type="table" rid="T1">Table 1</xref>]. The data analysis indicated that there was no significant difference in <italic>H. pylori</italic> complete eradication between males and females in the two groups [Tables <xref ref-type="table" rid="T2">2</xref> and <xref ref-type="table" rid="T3">3</xref>].</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>The rate of eradication and response to <italic>Helicobacter pylori</italic> in different age groups</p></caption><graphic xlink:href="JAPTR-8-63-g001"/></table-wrap><p>Furthermore, the findings indicated that the number of males and females with full eradication of <italic>H. pylori</italic> in the CAO- and CMO-treated groups was not significantly different [Tables <xref ref-type="table" rid="T2">2</xref> and <xref ref-type="table" rid="T3">3</xref>].</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Eradication rate of <italic>Helicobacter pylori</italic> infection in both sexes between the two treatment groups</p></caption><graphic xlink:href="JAPTR-8-63-g002"/></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Rate of eradication and response to <italic>Helicobacter pylori</italic> treatment in two groups</p></caption><graphic xlink:href="JAPTR-8-63-g003"/></table-wrap><p>Overall, the data analysis, irrespective of age and gender, indicated that the response rate was 87.2% for CAO regimen and 92.5% for CMO regimen with no significant difference in the eradication rate between the two regimens. <xref ref-type="table" rid="T3">Table 3</xref> shows the comparison of the two studied regimens.</p><p>Regarding side effects, three patients exhibited intolerance to clarithromycin and no side effects were seen due to amoxicillin and metronidazole in this study. No difference was seen in side effects between the two groups.</p></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>Long-term single use of clarithromycin for respiratory tract diseases has caused increased resistance to it. Resistance to clarithromycin is the most important reason for failure of <italic>H. pylori</italic> treatmentand decline in its eradication rate.[<xref rid="ref10" ref-type="bibr">10</xref>] The resistance rate to clarithromycin was obtained at 11.1%, 18.9%, and 29.3% in 2011 in Europe, Asia, and Americas, respectively.[<xref rid="ref11" ref-type="bibr">11</xref>] Several studies have found the decline in this regimen efficacy due to increased resistance to clarithromycin.[<xref rid="ref12" ref-type="bibr">12</xref><xref rid="ref13" ref-type="bibr">13</xref><xref rid="ref14" ref-type="bibr">14</xref>]</p><p>Metronidazole is used to treat anaerobic bacterial diseases, ameba, giardiasis, oral infections, and vaginosis and it has side effects including nausea, dyspepsia, pain, abdominal cramps, constipation, hairy tongue, glossitis, dry mouth, and bad taste,[<xref rid="ref15" ref-type="bibr">15</xref><xref rid="ref16" ref-type="bibr">16</xref>] none of which were seen in the patients of the present study.</p><p>Antelo <italic>et al</italic>. studied 120 patients assigned to three groups in Argentina. The eradication rate of the three regimens was reported to be similar, and the regimen administered for the Group 1 was offered as the best regimen because of fewer side effects.[<xref rid="ref17" ref-type="bibr">17</xref>] Regarding eradication rate, this study is consistent with the present study. However, the side effects were similar to the present study. A study by Treiber <italic>et al</italic>. demonstrated that the effect of CMO was compared with that of CMO + amoxicillin on <italic>H. pylori</italic> eradication, and an effective and safe new regimen for <italic>H. pylori</italic> eradication with no major side effects was reported.[<xref rid="ref18" ref-type="bibr">18</xref>]</p><p>In a study in China, different three-drug regimens were compared for treatment of the wounds due to <italic>H. pylori</italic> infection within a 1-year follow-up. The eradication rate of amoxicillin-contained and metronidazole-contained three-drug regimens administered for 14 days was 92.3% and 86%, respectively, and 7-day amoxicillin-contained three-drug regimen was offered as the best regimen because of the lowest recurrence rate of the wounds,[<xref rid="ref19" ref-type="bibr">19</xref>] which is partially consistent with the present study.</p><p>However, in a systematic review of 75 articles, the eradication rate of PPI + amoxicillin + clarithromycin and PPI + metronidazole + clarithromycin regimens was 83.5% and 68.6%, respectively. All the three regimens were administered for 14 days,[<xref rid="ref20" ref-type="bibr">20</xref>] which could be due to the difference in the studied geographical regions and high prevalence of resistance to metronidazole in these regions.</p><p>Moreover, a study by Paoluzi <italic>et al</italic>. in 2006 in Italy on 486 patients to compare 1- and 2-week three-drug regimens concluded that the eradication rate of the 2-week treatment was much higher than the 1-week treatment, and the eradication rate of amoxicillin-contained three-drug regimen was much higher than that of metronidazole-contained one (70% and 52%, respectively),[<xref rid="ref21" ref-type="bibr">21</xref>] which is lower than the eradication rate obtained for both regimens in the present study. This could be explained by high resistance to clarithromycin and metronidazole in the area of study.</p><p>In a systematic review in Iran, <italic>H. pylori</italic> resistance to metronidazole, clarithromycin, amoxicillin, was 61.6%, 22.4%, and 16.0%, respectively.[<xref rid="ref22" ref-type="bibr">22</xref>] In Khademi study in Isfahan, Iran, <italic>H. pylori</italic> resistance to clarithromycin, metronidazole, and amoxicillin was 15.3%, 55.1%, and 6.4%, respectively.[<xref rid="ref23" ref-type="bibr">23</xref>]</p><p>Inconsistent with the present study, a study by Kutluk <italic>et al</italic>. reported only 50% of eradication rate in children of 2&#x02013;15 years of age for CAO.[<xref rid="ref24" ref-type="bibr">24</xref>] A study in China found 66.4% eradication rate for CAO in children,[<xref rid="ref19" ref-type="bibr">19</xref>] and a study in Turkey obtained the eradication rate of 64.4%.[<xref rid="ref24" ref-type="bibr">24</xref>] Culture and sensitivity tests were not conducted in this study that can be considered a limitation of this study.</p></sec><sec sec-type="conclusions" id="sec1-5"><title>CONCLUSION</title><p>The comparison of two therapeutic regimens, CAO and CMO, indicated no significant difference in complete recovery and <italic>H. pylori</italic> eradication between the two regimens. The side effects were approximately similar in the two studied groups. Therefore, both regimens could be used to eliminate <italic>H. pylori</italic> infection and treat the patients with such infection.</p><sec id="sec2-1"><title>Financial support and sponsorship</title><p>Nil.</p></sec><sec id="sec2-2" sec-type="COI-statement"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></sec></body><back><ack><title>Acknowledgments</title><p>The present study was obtained from a research project at and funded by the Research and Technology Deputy of Shahrekord University of Medical Sciences. We thank the staff of Hajar Hospital, Shahrekord, Clinical Research Unit of this hospital, and other people who assisted us in conducting this study.</p></ack><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatakeyama</surname><given-names>M</given-names></name></person-group><article-title><italic>Helicobacter pylori</italic> and gastric carcinogenesis</article-title><source>J Gastroenterol</source><year>2009</year><volume>44</volume><fpage>239</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">19271114</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delport</surname><given-names>W</given-names></name><name><surname>Cunningham</surname><given-names>M</given-names></name><name><surname>Olivier</surname><given-names>B</given-names></name><name><surname>Preisig</surname><given-names>O</given-names></name><name><surname>van der Merwe</surname><given-names>SW</given-names></name></person-group><article-title>A population genetics pedigree perspective on the transmission of <italic>Helicobacter pylori</italic></article-title><source>Genetics</source><year>2006</year><volume>174</volume><fpage>2107</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">17057244</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guarner</surname><given-names>J</given-names></name><name><surname>Bartlett</surname><given-names>J</given-names></name><name><surname>Whistler</surname><given-names>T</given-names></name><name><surname>Pierce-Smith</surname><given-names>D</given-names></name><name><surname>Owens</surname><given-names>M</given-names></name><name><surname>Kreh</surname><given-names>R</given-names></name><etal/></person-group><article-title>Can pre-neoplastic lesions be detected in gastric biopsies of children with <italic>Helicobacter pylori</italic> infection?</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2003</year><volume>37</volume><fpage>309</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">12960654</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>S</given-names></name><name><surname>Nakajima</surname><given-names>S</given-names></name><name><surname>Nishino</surname><given-names>Y</given-names></name><name><surname>Ozawa</surname><given-names>K</given-names></name><name><surname>Minoura</surname><given-names>T</given-names></name><name><surname>Konno</surname><given-names>M</given-names></name><etal/></person-group><article-title>Association between gastric atrophy and <italic>Helicobacter pylori</italic> infection in Japanese children: A retrospective multicenter study</article-title><source>Dig Dis Sci</source><year>2006</year><volume>51</volume><fpage>99</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">16416219</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricuarte</surname><given-names>O</given-names></name><name><surname>Gutierrez</surname><given-names>O</given-names></name><name><surname>Cardona</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>JG</given-names></name><name><surname>Graham</surname><given-names>DY</given-names></name><name><surname>El-Zimaity</surname><given-names>HM</given-names></name></person-group><article-title>Atrophic gastritis in young children and adolescents</article-title><source>J Clin Pathol</source><year>2005</year><volume>58</volume><fpage>1189</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">16254110</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guarner</surname><given-names>J</given-names></name><name><surname>Kalach</surname><given-names>N</given-names></name><name><surname>Elitsur</surname><given-names>Y</given-names></name><name><surname>Koletzko</surname><given-names>S</given-names></name></person-group><article-title><italic>Helicobacter pylori</italic> diagnostic tests in children: Review of the literature from 1999 to 2009</article-title><source>Eur J Pediatr</source><year>2010</year><volume>169</volume><fpage>15</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">19618211</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Cherry</surname><given-names>JD</given-names></name><name><surname>Harrison</surname><given-names>GJ</given-names></name><name><surname>Kaplan</surname><given-names>SL</given-names></name><name><surname>Hotez</surname><given-names>PJ</given-names></name><name><surname>Steinbach</surname><given-names>WJ</given-names></name></person-group><source>Feigin and Cherry's Textbook of Pediatric Infectious Diseases</source><year>2014</year><edition>7th ed</edition><publisher-loc>Philadelphia</publisher-loc><publisher-name>Elsevier/Saunders</publisher-name><fpage>1996</fpage></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kliegman</surname><given-names>R</given-names></name><name><surname>Behrman</surname><given-names>RE</given-names></name><name><surname>Nelson</surname><given-names>WE</given-names></name></person-group><source>Nelson Textbook of Pediatrics</source><year>2016</year><edition>20th ed</edition><publisher-loc>Philadelphia, PA</publisher-loc><publisher-name>Elsevier/Saunders</publisher-name><fpage>1818</fpage></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000e9;graud</surname><given-names>F</given-names></name></person-group><article-title><italic>H. pylori</italic> antibiotic resistance: Prevalence, importance, and advances in testing</article-title><source>Gut</source><year>2004</year><volume>53</volume><fpage>1374</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">15306603</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Francesco</surname><given-names>V</given-names></name><name><surname>Giorgio</surname><given-names>F</given-names></name><name><surname>Hassan</surname><given-names>C</given-names></name><name><surname>Manes</surname><given-names>G</given-names></name><name><surname>Vannella</surname><given-names>L</given-names></name><name><surname>Panella</surname><given-names>C</given-names></name><etal/></person-group><article-title>Worldwide <italic>H. pylori</italic> antibiotic resistance: A systematic review</article-title><source>J Gastrointestin Liver Dis</source><year>2010</year><volume>19</volume><fpage>409</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">21188333</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paoluzi</surname><given-names>OA</given-names></name><name><surname>Visconti</surname><given-names>E</given-names></name><name><surname>Andrei</surname><given-names>F</given-names></name><name><surname>Tosti</surname><given-names>C</given-names></name><name><surname>Lionetti</surname><given-names>R</given-names></name><name><surname>Grasso</surname><given-names>E</given-names></name><etal/></person-group><article-title>Ten and eight-day sequential therapy in comparison to standard triple therapy for eradicating <italic>Helicobacter pylori</italic> infection: A randomized controlled study on efficacy and tolerability</article-title><source>J Clin Gastroenterol</source><year>2010</year><volume>44</volume><fpage>261</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">20195162</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kearney</surname><given-names>DJ</given-names></name><name><surname>Brousal</surname><given-names>A</given-names></name></person-group><article-title>Treatment of <italic>Helicobacter pylori</italic> infection in clinical practice in the United States: Results from 224 patients</article-title><source>Dig Dis Sci</source><year>2000</year><volume>45</volume><fpage>265</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">10711436</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malfertheiner</surname><given-names>P</given-names></name><name><surname>Bazzoli</surname><given-names>F</given-names></name><name><surname>Delchier</surname><given-names>JC</given-names></name><name><surname>Celi&#x000f1;ski</surname><given-names>K</given-names></name><name><surname>Gigu&#x000e8;re</surname><given-names>M</given-names></name><name><surname>Rivi&#x000e8;re</surname><given-names>M</given-names></name><etal/></person-group><article-title><italic>Helicobacter pylori</italic> eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: A randomised, open-label, non-inferiority, phase 3 trial</article-title><source>Lancet</source><year>2011</year><volume>377</volume><fpage>905</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">21345487</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>RJ</given-names><suffix>Jr</suffix></name><name><surname>Brown</surname><given-names>BA</given-names></name><name><surname>Griffith</surname><given-names>DE</given-names></name></person-group><article-title>Drug intolerance to high-dose clarithromycin among elderly patients</article-title><source>Diagn Microbiol Infect Dis</source><year>1993</year><volume>16</volume><fpage>215</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">8477575</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>DH</given-names></name><name><surname>Clissold</surname><given-names>SP</given-names></name></person-group><article-title>Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential</article-title><source>Drugs</source><year>1992</year><volume>44</volume><fpage>117</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">1379907</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>DY</given-names></name><name><surname>Abudayyeh</surname><given-names>S</given-names></name><name><surname>El-Zimaity</surname><given-names>HM</given-names></name><name><surname>Hoffman</surname><given-names>J</given-names></name><name><surname>Reddy</surname><given-names>R</given-names></name><name><surname>Opekun</surname><given-names>AR</given-names></name></person-group><article-title>Sequential therapy using high-dose esomeprazole-amoxicillin followed by gatifloxacin for <italic>Helicobacter pylori</italic> infection</article-title><source>Aliment Pharmacol Ther</source><year>2006</year><volume>24</volume><fpage>845</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">16918889</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antelo</surname><given-names>P</given-names></name><name><surname>Almuzara</surname><given-names>M</given-names></name><name><surname>Avagnina</surname><given-names>A</given-names></name><name><surname>Topor</surname><given-names>J</given-names></name><name><surname>Barberis</surname><given-names>C</given-names></name><name><surname>Barcia</surname><given-names>T</given-names></name><etal/></person-group><article-title>Diagnosis and treatment of <italic>Helicobacter pylori</italic> infection. Its relationship with gastrointestinal ulcer and antimicrobial resistance</article-title><source>Medicina (B Aires)</source><year>2001</year><volume>61</volume><issue>5 Pt 1</issue><fpage>545</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">11721321</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Treiber</surname><given-names>G</given-names></name><name><surname>Ammon</surname><given-names>S</given-names></name><name><surname>Schneider</surname><given-names>E</given-names></name><name><surname>Klotz</surname><given-names>U</given-names></name></person-group><article-title>Amoxicillin/metronidazole/omeprazole/clarithromycin: A new, short quadruple therapy for <italic>Helicobacter pylori</italic> eradication</article-title><source>Helicobacter</source><year>1998</year><volume>3</volume><fpage>54</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9546119</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Hou</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Song</surname><given-names>Z</given-names></name><etal/></person-group><article-title>A comparative study of sequential therapy and standard triple therapy for <italic>Helicobacter pylori</italic> infection: A randomized multicenter trial</article-title><source>Am J Gastroenterol</source><year>2014</year><volume>109</volume><fpage>535</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">24642580</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khademi</surname><given-names>F</given-names></name><name><surname>Poursina</surname><given-names>F</given-names></name><name><surname>Hosseini</surname><given-names>E</given-names></name><name><surname>Akbari</surname><given-names>M</given-names></name><name><surname>Safaei</surname><given-names>HG</given-names></name></person-group><article-title><italic>Helicobacter pylori</italic> in Iran: A systematic review on the antibiotic resistance</article-title><source>Iran J Basic Med Sci</source><year>2015</year><volume>18</volume><fpage>2</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">25810869</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paoluzi</surname><given-names>P</given-names></name><name><surname>Iacopini</surname><given-names>F</given-names></name><name><surname>Crispino</surname><given-names>P</given-names></name><name><surname>Nardi</surname><given-names>F</given-names></name><name><surname>Bella</surname><given-names>A</given-names></name><name><surname>Rivera</surname><given-names>M</given-names></name><etal/></person-group><article-title>2-week triple therapy for <italic>Helicobacter pylori</italic> infection is better than 1-week in clinical practice: A large prospective single-center randomized study</article-title><source>Helicobacter</source><year>2006</year><volume>11</volume><fpage>562</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17083378</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keshavarz Azizi Raftar</surname><given-names>S</given-names></name><name><surname>Moniri</surname><given-names>R</given-names></name><name><surname>Saffari</surname><given-names>M</given-names></name><name><surname>Razavi Zadeh</surname><given-names>M</given-names></name><name><surname>Arj</surname><given-names>A</given-names></name><name><surname>Mousavi</surname><given-names>SG</given-names></name><etal/></person-group><article-title>The <italic>Helicobacter pylori</italic> resistance rate to clarithromycin in Iran</article-title><source>Microb Drug Resist</source><year>2015</year><volume>21</volume><fpage>69</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">25144338</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khademi</surname><given-names>F</given-names></name><name><surname>Faghri</surname><given-names>J</given-names></name><name><surname>Poursina</surname><given-names>F</given-names></name><name><surname>Esfahani</surname><given-names>BN</given-names></name><name><surname>Moghim</surname><given-names>S</given-names></name><name><surname>Fazeli</surname><given-names>H</given-names></name><etal/></person-group><article-title>Resistance pattern of <italic>Helicobacter pylori</italic> strains to clarithromycin, metronidazole, and amoxicillin in Isfahan, Iran</article-title><source>J Res Med Sci</source><year>2013</year><volume>18</volume><fpage>1056</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">24523796</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kutluk</surname><given-names>G</given-names></name><name><surname>Tutar</surname><given-names>E</given-names></name><name><surname>Bayrak</surname><given-names>A</given-names></name><name><surname>Volkan</surname><given-names>B</given-names></name><name><surname>Akyon</surname><given-names>Y</given-names></name><name><surname>Celikel</surname><given-names>C</given-names></name><etal/></person-group><article-title>Sequential therapy versus standard triple therapy for <italic>Helicobacter pylori</italic> eradication in children: Any advantage in clarithromycin-resistant strains?</article-title><source>Eur J Gastroenterol Hepatol</source><year>2014</year><volume>26</volume><fpage>1202</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">25171023</pub-id></element-citation></ref></ref-list></back></article>